Benjamin M. Greenberg, MD, MHS & Professor Anthony Traboulsee, MD - Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.